Back to top
more

Evolus (EOLS)

(Real Time Quote from BATS)

$9.11 USD

9.11
1,172,454

-0.04 (-0.44%)

Updated Aug 4, 2025 03:43 PM ET

After-Market: $9.15 +0.04 (0.44%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -30.77% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

Zacks Equity Research

Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Computer Programs and Systems (CPSI) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -45% and 0.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in PetIQ (PETQ): Can Its 7.1% Jump Turn into More Strength?

by Zacks Equity Research

PetIQ (PETQ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.